Alerts will be sent to your verified email
Verify Email
ZIMLAB
|
Zim Laboratories
|
Medicamen Biotech
|
Shivalik Rasayan
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
6.9 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
7.41 % | 6.92 % | 6.54 % |
|
5yr average Equity Multiplier
|
1.88 | 1.44 | 1.82 |
|
5yr Average Asset Turnover Ratio
|
0.94 | 0.55 | 0.44 |
|
5yr Avg Net Profit Margin
|
4.15 % | 8.69 % | 7.94 % |
|
Price to Book
|
1.35 | 1.23 | 0.65 |
|
P/E
|
48.74 | 36.02 | 33.47 |
|
5yr Avg Cash Conversion Cycle
|
37.07 Days | 49.75 Days | 100.7 Days |
|
Inventory Days
|
68.72 Days | 84.58 Days | 80.64 Days |
|
Days Receivable
|
99.71 Days | 139.4 Days | 107.04 Days |
|
Days Payable
|
143.26 Days | 264.75 Days | 166.18 Days |
|
5yr Average Interest Coverage Ratio
|
3.96 | 7.03 | 8.55 |
|
5yr Avg ROCE
|
13.52 % | 10.34 % | 8.54 % |
|
5yr Avg Operating Profit Margin
|
12.21 % | 15.51 % | 17.6 % |
|
5 yr average Debt to Equity
|
0.39 | 0.15 | 0.2 |
|
5yr CAGR Net Profit
|
10.7 % | -11.57 % | -1.04 % |
|
5yr Average Return on Assets
|
4.02 % | 4.73 % | 3.57 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
33.26 % | 40.46 % | 47.37 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -2.75 % | -2.95 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Zim Laboratories
|
Medicamen Biotech
|
Shivalik Rasayan
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
|
Capex
|
Capex
|
-
|
-
|
|
Customer Segment
|
Customer Segment
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|